Parental perspectives on gene therapy for children with haemophilia: The Exigency study. Issue 1 (20th November 2020)

• Record Type: Journal Article
• Authors: Khair, Kate; Steadman, Lisa; Chaplin, Steve; Holland, Michael; Jenner, Kathryn; Fletcher, Simon
• Is Part Of: Haemophilia. Volume 27:Issue 1(2021)
• Page Start: 120
• Page End: 128
• Publication Date: 2020-11-20
• Subjects: child -- decision‐making -- gene therapy -- Haemophilia -- informed consent -- parents; Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.14188
• Languages: English
• ISSNs: 1351-8216

Abstract

Abstract: Introduction: Gene therapy is used in life‐limiting conditions of childhood. While not a current therapeutic option for children with haemophilia, it may be considered in the future especially for those where access to treatment is limited. Aim: To assess the attitudes and opinions of parents of children with haemophilia about gene therapy as a potential future treatment, by understanding their awareness about gene therapy and what they need to know now and in the future; gauging levels of interest in gene therapy for their children; and exploring perceived current motivations and barriers. Methods: A mixed methods study with an online questionnaire and in‐depth qualitative interviews in focus groups which were analysed using thematic analysis. Results: One hundred and fifty‐eight participants commenced the online survey; 63 were fully completed (39%). 60 had heard of gene therapy but few (17/60 [28.3%]) felt they had a good understanding. 38/60 (63.3%) respondents did not know that gene therapy is not available for children. However, most held positive views: 53/60 (88.3%) saying they would consider it for their child. In the interviews, participants ( N = 10, all mothers) discussed their awareness and understanding of gene therapy and opinions about it for children, including how this should be communicated to the child and parents. Conclusion: A coherent, community‐wide strategy for communicating information and news about gene therapy should now be provided for children and families living with haemophilia. This should come primarily from trusted haemophilia nursing teams, who can give tailored, age‐appropriate, factual advice.